Pharmacological Treatment of Cannabis Withdrawal and Dependence

大麻戒断和依赖性的药物治疗

基本信息

  • 批准号:
    8145249
  • 负责人:
  • 金额:
    $ 60.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-30 至 2016-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cannabis dependence (CD) is a worldwide public health problem. Treatments are of limited efficacy; one reason may be a failure to address the symptoms of withdrawal, such as craving and disturbances in affect and sleep, that may motivate resumed marijuana (MJ) use. In addition, heavy MJ use and withdrawal can impair executive functioning and thereby interfere with participation in cognitive therapies. The primary aim of this Phase II, single-site, 8-week, double-blind, placebo-controlled randomized clinical trial is to evaluate the efficacy of a novel neurokinin1 (NK1) receptor antagonist, vofopitant (5mg/day), for treating CD in 100 outpatients with current CD. The theoretical rationale for the anti-stress NK1 system as a novel target in CD is based on the neurobiology of abstinence in addiction which involves dysregulation in brain stress and reward systems, i.e., activation of brain stress systems in the amygdala, which vofopitant is hypothesized to normalize. In our Preliminary Studies we show vofopitant significantly decreased precipitated withdrawal symptoms in THC-dependent rats and provide positive results from a proof-of-principle controlled trial of gabapentin (also hypothesized to normalize brain stress circuitry) that found significantly reduced MJ use and withdrawal symptoms, including craving, mood and sleep, and improved executive functioning relative to placebo in 50 CD subjects. The primary hypotheses under test are that vofopitant will significantly improve symptoms of cannabis withdrawal, specifically craving, anxiety, mood and sleep, and reduce MJ use and MJ-related dysregulation of executive functioning and fMRI BOLD response to MJ cues and emotional cues significantly more than placebo in CD outpatients. We will apply the best innovative technology for evaluating the effect of vofopitant treatment on MJ use through a collaboration with Dr. Marilyn Huestis (NIDA/IRP), who will provide analysis of CN-THCOOH concentrations in subjects' weekly observed urine specimens, applying new detection models to identify new MJ use. A further novel aspect of the proposal is the evaluation of executive functioning in the context of a treatment protocol. Potential relationships between MJ use, MJ withdrawal and cognitive functioning will be examined statistically. A further aim of this project is to identify CD individuals most likely to benefit from vofopitant and to measure effects of vofopitant on these factors relative to placebo, thereby clarifying the mechanisms through which NK1 antagonists have efficacy in CD. Potential baseline predictors are: a.) Substance P, ACTH, cortisol and NE, b.) subjective measures of anxiety, mood, insomnia, craving and stress; c.) executive functioning; and d.) fMRI BOLD response to MJ cues, emotional cues and capacity for inhibition in the context of an Affective Go-No-Go task, and functional connectivity during resting state. Given the prevalence of CD and the lack of effective pharmacotherapies, the development of vofopitant as a novel medication for CD may have major public health benefits. PUBLIC HEALTH RELEVANCE: Cannabis is the most widely used illicit drug in the US and there are no FDA-approved treatments for cannabis dependence (CD). The purpose of this application is to conduct a Phase II clinical trial to assess the efficacy of a novel NK1 antagonist, vofopitant, as a new treatment for CD. The development of vofopitant as a novel medication for CD may have major public health benefits and is highly significant for the mission of NIDA.
描述(由申请人提供):大麻依赖(CD)是一个全球性的公共卫生问题。治疗效果有限;一个原因可能是未能解决戒断症状,如渴望、情感和睡眠紊乱,这可能会促使大麻(MJ)重新使用。此外,重度MJ使用和戒断会损害执行功能,从而干扰认知治疗的参与。该II期单点、8周、双盲、安慰剂对照随机临床试验的主要目的是评估一种新型神经激肽1 (NK1)受体拮抗剂伏伏匹坦(5mg/天)治疗100例门诊CD患者的效果。抗应激NK1系统作为CD的新靶点的理论基础是基于成瘾戒断的神经生物学,其中涉及大脑应激和奖励系统的失调,即:激活杏仁核中的大脑应激系统,伏伏匹坦被假设使其正常化。在我们的初步研究中,我们发现伏伏匹坦显著减少了四氢大麻酚依赖大鼠的急性戒断症状,并从加巴喷丁(也假设使脑应激回路正常化)的原理验证对照试验中提供了积极的结果,该试验发现在50名CD受试者中,与安慰剂相比,显著减少了MJ的使用和戒断症状,包括渴望、情绪和睡眠,并改善了执行功能。被检验的主要假设是,伏福匹坦将显著改善大麻戒断症状,特别是渴望、焦虑、情绪和睡眠,并减少MJ使用和MJ相关的执行功能失调,以及fMRI BOLD对MJ线索和情绪线索的反应,显著高于安慰剂。我们将通过与Marilyn Huestis博士(NIDA/IRP)的合作,应用最好的创新技术来评估福匹坦治疗对MJ使用的影响,Marilyn Huestis博士将提供受试者每周观察尿液标本中CN-THCOOH浓度的分析,应用新的检测模型来识别新的MJ使用。该建议的另一个新颖方面是在治疗方案的背景下评估执行功能。MJ使用、MJ戒断和认知功能之间的潜在关系将在统计学上进行检验。该项目的另一个目的是确定最有可能受益于伏伏匹坦的乳糜泻患者,并测量伏伏匹坦相对于安慰剂对这些因素的影响,从而阐明NK1拮抗剂对乳糜泻有效的机制。潜在的基线预测因子是:P物质、ACTH、皮质醇和NE, b)焦虑、情绪、失眠、渴望和压力的主观测量;c)执行功能;d. fMRI BOLD对MJ线索、情绪线索和情感Go-No-Go任务背景下的抑制能力的反应,以及静息状态下的功能连接。鉴于乳糜泻的流行和缺乏有效的药物治疗,开发伏福匹坦作为乳糜泻的新型药物可能具有重大的公共卫生益处。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BARBARA J MASON其他文献

BARBARA J MASON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BARBARA J MASON', 18)}}的其他基金

CNS Effects of Alcohol: Cellular Neurobiology
酒精对中枢神经系统的影响:细胞神经生物学
  • 批准号:
    10834659
  • 财政年份:
    2023
  • 资助金额:
    $ 60.12万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10848509
  • 财政年份:
    2023
  • 资助金额:
    $ 60.12万
  • 项目类别:
CNS Effects of Alcohol: Cellular Neurobiology
酒精对中枢神经系统的影响:细胞神经生物学
  • 批准号:
    10419301
  • 财政年份:
    2021
  • 资助金额:
    $ 60.12万
  • 项目类别:
Proof-of-Concept Human Laboratory Testing of Novel Drug Candidates Identified by INIA-NeuroImmune
INIA-NeuroImmune 确定的新候选药物的概念验证人体实验室测试
  • 批准号:
    9241910
  • 财政年份:
    2017
  • 资助金额:
    $ 60.12万
  • 项目类别:
Medication Development for Protracted Abstinence in Alcoholism
长期戒酒的药物开发
  • 批准号:
    9110767
  • 财政年份:
    2015
  • 资助金额:
    $ 60.12万
  • 项目类别:
Recent Frontiers and Advances in Drug Addiction (IDARS Conference)
吸毒成瘾的最新前沿和进展(IDARS 会议)
  • 批准号:
    8986683
  • 财政年份:
    2015
  • 资助金额:
    $ 60.12万
  • 项目类别:
Glucocorticoid Antagonist Treatment of Alcohol Use Disorder
糖皮质激素拮抗剂治疗酒精使用障碍
  • 批准号:
    8803452
  • 财政年份:
    2014
  • 资助金额:
    $ 60.12万
  • 项目类别:
Glucocorticoid Antagonist Treatment of Alcohol Use Disorder
糖皮质激素拮抗剂治疗酒精使用障碍
  • 批准号:
    8917076
  • 财政年份:
    2014
  • 资助金额:
    $ 60.12万
  • 项目类别:
Glucocorticoid Antagonist Treatment of Alcohol Use Disorder
糖皮质激素拮抗剂治疗酒精使用障碍
  • 批准号:
    9102731
  • 财政年份:
    2014
  • 资助金额:
    $ 60.12万
  • 项目类别:
Pharmacological Treatment of Cannabis Withdrawal and Dependence
大麻戒断和依赖性的药物治疗
  • 批准号:
    8788513
  • 财政年份:
    2010
  • 资助金额:
    $ 60.12万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了